APLS - Company ID 0001492422
The table below shows Apellis Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $405.21M | $479.17M | $370.04M | $358.39M | $396.86M | $360.09M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $440.30M | $345.54M | $214.13M | $235.25M | $279.01M | $304.43M |
| Inventory | $131.41M | $122.82M | $121.00M | $82.47M | $121.06M | $152.77M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.03B |
| $990.68M |
| $755.61M |
| $727.72M |
| $833.90M |
| $859.97M |
| Property, plant & equipment | $1.42M | $1.93M | $2.12M | $2.51M | $3.38M | $3.84M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.08B | $1.06B | $821.39M | $807.28M | $901.87M | $904.48M |
| Accounts payable | $49.05M | $38.60M | $54.24M | $55.29M | $42.73M | $38.27M |
| Total current liabilities | $283.45M | $279.53M | $200.66M | $178.38M | $191.26M | $169.17M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $667.61M | $657.55M | $665.09M | $643.07M | $664.75M | $640.15M |
| Retained earnings | -$2.99B | -$2.95B | -$3.17B | -$3.13B | -$3.00B | -$2.94B |
| Total equity | $414.92M | $401.17M | $156.31M | $164.22M | $237.12M | $264.33M |